Abstract
In aretrospective study, we analyzed the prevalence of common cardiovascular comorbidities in 310patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with laboratory and molecular features. 115 (36%) patients had adocumented cardiovascular comorbidity. In these patients, coronary heart disease 41/115 (36%), atrial fibrillation 34/115 (29%), and hypertension 75/115 (64%) were documented. None of these conditions had asignificant impact on survival. Unexpectedly, patients with cardiovascular comorbidity had alower number of circulating blasts and alower prevalence of EZH2 mutations. Moreover, time to transformation was significantly longer in these patients. Cardiovascular comorbidity does not seem to have amajor impact on prognosis in CMML patients. The unexpected lower transformation rate in these patients needs to be further investigated.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
